Gyre Therapeutics, Inc.
NASDAQ:GYREBiotechnology
Healthcare
$4.34 -0.15%
+$0.00 today
- Market cap
- $475.02M
- Beta
- 4.92
- P/E (TTM)
- -88.3
- EPS (TTM)
- -$0.07
52W Low $5.44High $9.42
Volume 0.47M
Average 0.09M
Income Statement
Follow revenue through to earnings.
Revenue
$116.59M
FY 2025 · Annual
+10.2% YoYOperating Income
$11.49M
FY 2025 · Annual
-28.9% YoYNet Income
$5.03M
FY 2025 · Annual
-58.4% YoYIncome Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.34M | 102.29M | 113.45M | 105.76M | 116.59M |
| Cost of Revenue | 7.67M | 4.79M | 4.64M | 3.88M | 5.42M |
| Gross Profit | (332K) | 97.5M | 108.81M | 101.87M | 111.17M |
| Gross Margin | -4.5% | 95.3% | 95.9% | 96.3% | 95.4% |
| Research & Development | 64.57M | 16.69M | 13.78M | 12.02M | 13.7M |
| Selling, General & Admin | 18.82M | 71.61M | 75.82M | 73.62M | 85.98M |
| Operating Expenses | 83.39M | 88.29M | 176.04M | 85.71M | 99.68M |
| Depreciation & Amortization | 290K | 1.13M | 1.11M | 1.59M | 2.52M |
| EBITDA | (87.64M) | 10.54M | 20.33M | 17.82M | 16.96M |
| EBITDA Margin | -1194.4% | 10.3% | 17.9% | 16.8% | 14.5% |
| Operating Income | (83.73M) | 9.2M | (67.23M) | 16.16M | 11.49M |
| Operating Margin | -1141.0% | 9.0% | -59.3% | 15.3% | 9.9% |
| Interest Income | 39K | 726K | 1.04M | 1.55M | 1.75M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (4.21M) | 209K | (9.74M) | 7.06M | 2.95M |
| Income Before Tax | (87.93M) | 9.41M | (76.97M) | 23.22M | 14.44M |
| Pre-Tax Margin | -1198.3% | 9.2% | -67.8% | 22.0% | 12.4% |
| Income Tax Expense | 0 | 5.1M | 8.52M | 5.32M | 4.56M |
| Net Income | (87.93M) | 2.3M | (92.93M) | 12.09M | 5.03M |
| Net Margin | -1198.3% | 2.3% | -81.9% | 11.4% | 4.3% |
| EPS (Basic) | (2.87) | 0.03 | (1.41) | 0.14 | 0.06 |
| EPS (Diluted) | (2.87) | 0.03 | (1.41) | 0.05 | 0.02 |
| 30.64M | 76.74M | 65.83M | 85.09M | 89.34M | |
| 30.64M | 75.69M | 65.83M | 102.29M | 103.18M |
GYRE Earnings Waterfall · TTM
NASDAQ:GYRE · Revenue to Net Income
Key Ratios
EPS$-0.08
Gross Margin95.1%
Net Margin-7.4%
P/E Ratio76.2
P/S Ratio22.9
Analysis
$117.0M of revenue converted into -$6.3M of net income for the selected period. Gross margin is 95.1% and net margin is -7.4%, showing how much revenue survives after costs and taxes. EPS is $-0.08, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 8-K | Current report | Oct 22, 2026 | |
| 8-K | Current report | Sep 1, 2026 | |
| S-8 | S-8 filing | Aug 27, 2026 |
How much revenue does GYRE generate?
Gyre Therapeutics, Inc. (GYRE) reported $116.59M of revenue in fiscal 2025.
Is GYRE profitable?
Gyre Therapeutics, Inc. (GYRE) reported $5.03M of net income, with a net margin of 4.3%.
Continue the stock analysis
Jump to another research area for this company.